24252-37-7

Basic information

• Product Name: Ethyl 1-methyl-4-piperidinecarboxylate
• Synonyms: ETHYL 1-METHYLPIPERIDINE-4-CARBOXYLATE;1-METHYL-PIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER;ETHYL 1-METHYL-4-PIPERIDINECARBOXYLATE;N-Methyl ethyl isonipecotate;REF DUPL: 1-Methyl-piperidine-4-carboxylic acid ethyl ester;Ethyl N-Methyl piperidine-4-carboxylate;Ethyl 1-methylisonipecotate, 4-(Ethoxycarbonyl)-1-methylpiperidine;Ethyl 1-Methylpiperidine-4-carboxylate, 97+%
• CAS NO: 24252-37-7
• Molecular Formula: C₉H₁₇NO₂
• Molecular Weight: 171.24
• Product Categories: Heterocyclic Compounds
• Mol File: 24252-37-7.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 211.12 °C at 760 mmHg
• Flash Point: 87℃
• Appearance: /
• Density: 0.963 g/mL at 25 °C
• Vapor Pressure: 0.186mmHg at 25°C
• Refractive Index: n20/D1.450
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.50±0.10(Predicted)
• CAS DataBase Reference: Ethyl 1-methyl-4-piperidinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 1-methyl-4-piperidinecarboxylate(24252-37-7)
• EPA Substance Registry System: Ethyl 1-methyl-4-piperidinecarboxylate(24252-37-7)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41
• Safety Statements: 26-36/37/39
• RIDADR: NA 1993 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 24252-37-7(Hazardous Substances Data)

Usage

Chemical Properties

Colorless liquid

Uses

Reactant for synthesis of:Piperidine derivatives as inhibitors of S. aureus and E. coli enoyl-ACP reductaseGABAA receptor agonistsWater-soluble DNA-binding subunits for analogues of cytotoxic antibiotic CC-1065 and their prodrugsTricyclic pharmaceuticals5-HT3 antagonists

InChI:InChI=1/C9H17NO2/c1-3-12-9(11)8-4-6-10(2)7-5-8/h8H,3-7H2,1-2H3

Upstream product

• 1126-09-6 4-carbethoxypiperidine 
• 50-00-0 formaldehyd 
• 74-87-3 methylene chloride 
• 40175-06-2 ethyl 1-methyl-1,2,5,6-tetrahydropyridine-4-carboxylate 
• 824-77-1 4-carboxy-1-methylpyridinium inner salt monohydrate 
• 67-56-1 methanol 
• 74-88-4 methyl iodide 
• 10129-59-6 1-methyl-4-ethoxycarbonylpyridinium iodide 
• 1570-45-2 isonicotinic acid ethylester 
• 68947-43-3 1-methylpiperidine-4-carboxylic acid 

Downstream Products

• 102076-17-5 4-benzoyl-1-methyl-piperidine-4-carboxylic acid ethyl ester 
• 20691-89-8 1-methyl-4-piperidinemethanol 
• 229003-66-1 4-ethoxycarbonyl-1-methyl-1-[4-(7-phenyl-3,4-dihydronaphthalene-2-carboxamido)benzyl]piperidinium chloride 
• 50675-21-3 N-methyl-piperidine-4-carboxaldehyde 
• 439239-90-4 Lasmiditan 
• 1228552-71-3 9-methyl-2,9-diazaspiro[5.5]undecan-1-one 
• 162648-33-1 1,4-dimethylpiperidine-4-carboxylic acid 
• 408306-81-0 ethyl 1,4-dimethylpiperidine-4-carboxylate 
• 147083-36-1 11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine 
• 71985-80-3 1-methylpiperidine-4-carboxylic acid hydrochloride 
• 176178-88-4 1-methyl-piperidine-4-carboxylic acid hydrazide 
• 19999-64-5 1-methyl-3-piperidinecarboxylic acid hydrochloride 
• 68947-43-3 1-methylpiperidine-4-carboxylic acid 
• 41632-36-4 4-acetoxymethyl-1,1-dimethyl-piperidinium; iodide 

Relevant articles and documents

-

-

CONTROLLED RELEASE PREPARATION

A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.

Water-Soluble CC-1065 Analogs and Their Conjugates

This invention relates to novel analogs of the DNA-binding alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.